Moderna expects cash, cash equivalents to be approx. $1.7B as of Dec. 31

The company said, “We expect our cash, cash equivalents, and investments in marketable securities as of December 31, 2018 to be approximately $1.7B as compared to $902M as of December 31, 2017. The year over year increase includes approximately $564M in net proceeds from our initial public offering completed in December 2018, approximately $661M in net proceeds from our preferred stock issuances in 2018, and a $13M premium associated with the 2018 amended and restated personalized cancer vaccines agreement with Merck & Co. (MRK).”
https://thefly.com/landingPageNews.php?id=2845445